Modifying murine von Willebrand factor A1 domain for in vivo assessment of human platelet therapies

Nature Biotechnology

Volumn 26, Issue 1, 2008, Pages 114-119

  Chen, Jianchun ^a   Tan, Kui ^a   Zhou, Hairu ^a   Lo, Hsuan Fu ^a   Roux, Diana Tronik Le ^b   Liddington, Robert C ^c   Diacovo, Thomas G ^a  

^a NewYork Presbyterian Hospital   (United States)

^b DIF   (France)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY; MAMMALS; PHYSIOLOGICAL MODELS;

ATOMIC MODELS; HEMOSTASIS; THROMBOSIS;

DISEASES;

ABCIXIMAB; CLOPIDOGREL; GLYCOPROTEIN IB ALPHA; MUTANT PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD VESSEL OCCLUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; THROMBOCYTE ADHESION; THROMBOCYTE TRANSFUSION; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; THROMBOSIS; VON WILLEBRAND FACTOR;

MURINAE; MUS;

EID: 38049036483     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1373     Document Type: Article

References (30)

1. Cruz, M.A., Diacovo, T.G., Emsley, J., Liddington, R. & Handin, R.I. Mapping the glycoprotein Ib-binding site in the von Willebrand factor A1 domain. J. Biol. Chem. 275, 19098-19105 (2000).
2. Sugimoto, M. et al. Functional modulation of the isolated glycoprotein Ib binding domain of von Willebrand factor expressed in Escherichia coli. Biochemistry 30, 5202-5209 (1991).
3. Pietu, G. et al. Production in Escherichia coli of a biologically active subfragment of von Willebrand factor corresponding to the platelet glycoprotein Ib, collagen and heparin binding domains. Biochem. Biophys. Res. Commun. 164, 1339-1347 (1989).
4. Savage, B., Saldivar, E. & Ruggeri, Z.M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84, 289-297 (1996).
5. Doggett, T.A. et al. Selectin-like kinetics and biomechanics promote rapid platelet adhesion in flow: the GPIb(alpha)-vWF tether bond. Biophys. J. 83, 194-205 (2002).
6. Whittaker, C.A. & Hynes, R.O. Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. Mol. Biol. Cell 13, 3369-3387 (2002).
7. Sakariassen, K.S., Bolhuis, P.A. & Sixma, J.J. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature 279, 636-638 (1979).
8. Canobbio, I., Balduini, C. & Torti, M. Signalling through the platelet glycoprotein Ib-V-IX complex. Cell. Signal. 16, 1329-1344 (2004).
9. Offermanns, S. Activation of platelet function through G protein-coupled receptors. Circ. Res. 99, 1293-1304 (2006).
10. Nieswandt, B. & Watson, S.P. Platelet-collagen interaction: is GPVI the central receptor? Blood 102, 449-461 (2003).
11. Shattil, S.J. & Newman, P.J. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 104, 1606-1615 (2004).
12. Hodivala-Dilke, K.M. et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103, 229-238 (1999).
13. Lopez, A.D., Mathers, C.D., Ezzati, M., Jamison, D.T. & Murray, C.J. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367, 1747-1757 (2006).
14. Hankey, G.J. & Eikelboom, J.W. Antiplatelet drugs. Med. J. Aust. 178, 568-574 (2003).
15. Bennett, J.S. Novel platelet inhibitors. Annu. Rev. Med. 52, 161-184 (2001).
16. Coughlin, S.R. Thrombin signalling and protease-activated receptors. Nature 407, 258-264 (2000).
17. Ruggeri, Z.M., Orje, J.N., Habermann, R., Federici, A.B. & Reininger, A.J. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 108, 1903-1910 (2006).
18. Fukuda, K., Doggett, T., Laurenzi, I.J., Liddington, R.C. & Diacovo, T.G. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat. Struct. Mol. Biol. 12, 152-159 (2005).
19. Dumas, J.J. et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J. Biol. Chem. 279, 23327-23334 (2004).
20. Huizinga, E.G. et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 297, 1176-1179 (2002).
21. Bogan, A.A. & Thorn, K.S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280, 1-9 (1998).
22. Shen, Y. et al. Requirement of leucine-rich repeats of glycoprotein (GP) Ibalpha for shear-dependent and static binding of von Willebrand factor to the platelet membrane GP Ib-IX-V complex. Blood 95, 903-910 (2000).
23. Fredrickson, B.J., Dong, J.F., McIntire, L.V. & Lopez, J.A. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 92, 3684-3693 (1998).
24. Furie, B. & Furie, B.C. Thrombus formation in vivo. J. Clin. Invest. 115, 3355-3362 (2005).
25. Ware, J., Russell, S. & Ruggeri, Z.M. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc. Natl. Acad. Sci. USA 97, 2803-2808 (2000).
26. Bergmeier, W. et al. The role of platelet adhesion receptor GPIbalpha far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc. Natl. Acad. Sci. USA 103, 16900-16905 (2006).
27. Denis, C. et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. USA 95, 9524-9529 (1998).
28. Diacovo, T.G., Puri, K.D., Warnock, R.A., Springer, T.A. & von Andrian, U.H. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 273, 252-255 (1996).
29. Collaborative Computational Project. No. 4 The CCP4 suite: programs for protein crystallography. Acta Crystallogr.D 50, 760-763 (1994).
30. Esnouf, R.M. An extensively modified version of Molscript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 15, 132-136 (1997).